Vipadenant (CEB-4520)(BIIB-014) is an adenosine A2a antagonist with Ki of 1.3 nM; less potent for A1(Ki=69 nM).

A2A:1.3 nM(Ki), A1:69 nM(Ki)

Vipadenant, administered at doses ranging from 0.3 to 30 mg/kg, effectively reduces catalepsy in a dose-dependent manner without inducing statistically significant dyskinetic episodes in 6-OHDA-lesioned rats at a dosage of 10 mg/kg through a 19-day treatment protocol. Moreover, in models of haloperidol-induced hypolocomotion in mice and rats, the minimum effective doses of vipadenant are 0.1 mg/kg and 1 mg/kg, respectively. Additionally, oral administration of vipadenant at 3 and 10 mg/kg is shown to increase contralateral rotations in 6-OHDA lesioned rats, indicating its potential in modulating motor functions.

Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl2, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 μM ATP/γ-32[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.

DMSO: 55 mg/mL (171.16 mM), Sonication is recommended.